Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription

Articles published in J Clin Invest

Retrieve available abstracts of 23 articles:
HTML format

Single Articles

    May 2021
  1. GIBLIN W, Bringman-Rodenbarger L, Guo AH, Kumar S, et al
    The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.
    J Clin Invest. 2021 May 4. pii: 138926. doi: 10.1172/JCI138926.
    PubMed     Abstract available

    April 2021
  2. KIM YJ, Sheu KM, Tsoi J, Abril-Rodriguez G, et al
    Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy.
    J Clin Invest. 2021 Apr 29. pii: 145859. doi: 10.1172/JCI145859.
    PubMed     Abstract available

    March 2021
  3. WORREDE A, Douglass SM, Weeraratna AT
    The dark side of daylight: photoaging and the tumor microenvironment in melanoma progression.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

  4. HUANG F, Goncalves C, Bartish M, Remy-Sarrazin J, et al
    Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses.
    J Clin Invest. 2021 Mar 9. pii: 140752. doi: 10.1172/JCI140752.
    PubMed     Abstract available

    May 2020
  5. SUCH L, Zhao F, Liu D, Thier B, et al
    Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
    J Clin Invest. 2020 May 19. pii: 131572. doi: 10.1172/JCI131572.
    PubMed     Abstract available

  6. LI J, Wang W, Zhang Y, Cieslik M, et al
    Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
    J Clin Invest. 2020;130:2712-2726.
    PubMed     Abstract available

  7. THEIVANTHIRAN B, Evans KS, DeVito NC, Plebanek M, et al
    A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
    J Clin Invest. 2020;130:2570-2586.
    PubMed     Abstract available

    January 2020
  8. LUO C, Balsa E, Perry EA, Liang J, et al
    H3K27me3-mediated PGC1alpha gene silencing promotes melanoma invasion through WNT5A and YAP.
    J Clin Invest. 2020 Jan 13. pii: 130038. doi: 10.1172/JCI130038.
    PubMed     Abstract available

    April 2019
  9. TUNCER E, Calcada RR, Zingg D, Varum S, et al
    SMAD signaling promotes melanoma metastasis independently of phenotype switching.
    J Clin Invest. 2019;130.
    PubMed     Abstract available

    March 2019
  10. MCEVOY CR, Xu H, Smith K, Etemadmoghadam D, et al
    Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.
    J Clin Invest. 2019;130.
    PubMed     Abstract available

    February 2019
  11. WALSH SR, Bastin D, Chen L, Nguyen A, et al
    Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.
    J Clin Invest. 2019;129:518-530.
    PubMed     Abstract available

    September 2018
  12. HUBER V, Vallacchi V, Fleming V, Hu X, et al
    Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.
    J Clin Invest. 2018 Sep 27. pii: 98060. doi: 10.1172/JCI98060.
    PubMed     Abstract available

    April 2018
  13. NSENGIMANA J, Laye J, Filia A, O'Shea S, et al
    beta-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
    J Clin Invest. 2018 Apr 16. pii: 95351. doi: 10.1172/JCI95351.
    PubMed     Abstract available

    January 2018
  14. VEATCH JR, Lee SM, Fitzgibbon M, Chow IT, et al
    Tumor infiltrating BRAFV600E-specific CD4 T cells correlated with complete clinical response in melanoma.
    J Clin Invest. 2018 Jan 23. pii: 98689. doi: 10.1172/JCI98689.
    PubMed     Abstract available

    December 2017
  15. TAMIYA H, Kim H, Klymenko O, Kim H, et al
    SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
    J Clin Invest. 2017 Dec 11. pii: 95410. doi: 10.1172/JCI95410.
    PubMed     Abstract available

  16. VENKATESAN AM, Vyas R, Gramann AK, Dresser K, et al
    Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma.
    J Clin Invest. 2017 Dec 4. pii: 92513. doi: 10.1172/JCI92513.
    PubMed     Abstract available

    October 2017
  17. ZHAN Y, Guo J, Yang W, Goncalves C, et al
    MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
    J Clin Invest. 2017 Oct 16. pii: 91258. doi: 10.1172/JCI91258.
    PubMed     Abstract available

    August 2017
  18. JESCHKE J, Bizet M, Desmedt C, Calonne E, et al
    DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.
    J Clin Invest. 2017;127:3090-3102.
    PubMed     Abstract available

  19. AYERS M, Lunceford J, Nebozhyn M, Murphy E, et al
    IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade.
    J Clin Invest. 2017;127:2930-2940.
    PubMed     Abstract available

    June 2017
  20. SMITH TT, Moffett HF, Stephan SB, Opel CF, et al
    Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.
    J Clin Invest. 2017;127:2176-2191.
    PubMed     Abstract available

    May 2017
  21. OLVEDY M, Tisserand JC, Luciani F, Boeckx B, et al
    Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.
    J Clin Invest. 2017 May 2. pii: 91291. doi: 10.1172/JCI91291.
    PubMed     Abstract available

    April 2017
  22. ANSA-ADDO EA, Zhang Y, Yang Y, Hussey GS, et al
    Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-beta signaling.
    J Clin Invest. 2017;127:1321-1337.
    PubMed     Abstract available

    September 2016
  23. JANOWSKI AM, Colegio OR, Hornick EE, McNiff JM, et al
    NLRC4 suppresses melanoma tumor progression independently of inflammasome activation.
    J Clin Invest. 2016 Sep 12. pii: 86953. doi: 10.1172/JCI86953.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.